WallStSmart

Cencora Inc. (COR)vsHenry Schein Inc (HSIC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 2356% more annual revenue ($328.68B vs $13.38B). HSIC leads profitability with a 3.0% profit margin vs 0.8%. COR appears more attractively valued with a PEG of 0.60. COR earns a higher WallStSmart Score of 64/100 (C+).

COR

Buy

64

out of 100

Grade: C+

Growth: 7.3Profit: 6.0Value: 5.3Quality: 5.0
Piotroski: 4/9Altman Z: 4.36

HSIC

Buy

52

out of 100

Grade: C-

Growth: 4.7Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: 2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORSignificantly Overvalued (-56.3%)

Margin of Safety

-56.3%

Fair Value

$180.05

Current Price

$275.04

$94.99 premium

UndervaluedFair: $180.05Overvalued
HSICUndervalued (+46.8%)

Margin of Safety

+46.8%

Fair Value

$153.40

Current Price

$77.45

$75.95 discount

UndervaluedFair: $153.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR6 strengths · Avg: 9.2/10
Return on EquityProfitability
75.0%10/10

Every $100 of equity generates 75 in profit

EPS GrowthGrowth
128.3%10/10

Earnings expanding 128.3% YoY

Altman Z-ScoreHealth
4.3610/10

Safe zone — low bankruptcy risk

Market CapQuality
$54.76B9/10

Large-cap with strong market position

PEG RatioValuation
0.608/10

Growing faster than its price suggests

Free Cash FlowQuality
$1.17B8/10

Generating 1.2B in free cash flow

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

COR4 concerns · Avg: 3.5/10
Price/BookValuation
15.8x4/10

Trading at 15.8x book value

Revenue GrowthGrowth
3.8%4/10

3.8% revenue growth

Profit MarginProfitability
0.8%3/10

0.8% margin — thin

Operating MarginProfitability
1.7%3/10

Operating margin of 1.7%

HSIC4 concerns · Avg: 3.5/10
PEG RatioValuation
1.794/10

Expensive relative to growth rate

EPS GrowthGrowth
4.5%4/10

4.5% earnings growth

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.153/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, EPS Growth, Altman Z-Score. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bear Case : COR

The primary concerns for COR are Price/Book, Revenue Growth, Profit Margin. Debt-to-equity of 3.65 is elevated, increasing financial risk. Thin 0.8% margins leave little buffer for downturns.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, EPS Growth, Profit Margin. Thin 3.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

HSIC carries more volatility with a beta of 0.82 — expect wider price swings.

HSIC is growing revenue faster at 6.3% — sustainability is the question.

COR generates stronger free cash flow (1.2B), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

COR scores higher overall (64/100 vs 52/100). HSIC offers better value entry with a 46.8% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?